GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Long-Term Debt

Diamyd Medical AB (FRA:DMN) Long-Term Debt : €0.00 Mil (As of Feb. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Long-Term Debt?

Diamyd Medical AB's Long-Term Debt for the quarter that ended in Feb. 2025 was €0.00 Mil.

Diamyd Medical AB's quarterly Long-Term Debt declined from Aug. 2024 (€2.68 Mil) to Nov. 2024 (€0.00 Mil) but then stayed the same from Nov. 2024 (€0.00 Mil) to Feb. 2025 (€0.00 Mil).

Diamyd Medical AB's annual Long-Term Debt increased from Aug. 2022 (€0.00 Mil) to Aug. 2023 (€1.34 Mil) and increased from Aug. 2023 (€1.34 Mil) to Aug. 2024 (€2.68 Mil).

Diamyd Medical AB Long-Term Debt Historical Data

The historical data trend for Diamyd Medical AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Long-Term Debt Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.34 2.68

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.68 - -

Diamyd Medical AB  (FRA:DMN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Diamyd Medical AB Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Long-Term Debt
Comparable Companies
OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE OSTO:XSPRAY OSTO:FLUO OSTO:IBT B OSTO:GENO OSTO:IRLAB A OSTO:EGTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
DMYD B:Sweden
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.